Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Exenatide × Clear all

Status

Sponsor Class

OTHER 12 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

pembrolizumab 848 Carboplatin 789 Paclitaxel 779 Gemcitabine 649 Cisplatin 627 Docetaxel 600 Bevacizumab 521 Nivolumab 417 Pemetrexed 410 Cyclophosphamide 396 Capecitabine 386 Fluorouracil 333 Dexamethasone 328 Rituximab 327 Oxaliplatin 284 Injections 280 atezolizumab 262 Trastuzumab 256 Cetuximab 236 Leucovorin 227 Irinotecan 216 Prednisone 215 130-nm albumin-bound paclitaxel 213 Doxorubicin 209 Ipilimumab 198 Lenalidomide 192 Fulvestrant 185 fludarabine 177 durvalumab 173 venetoclax 168

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05663515 2026-02-12

EXCEED

AstraZeneca

24,000 enrolled

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡